InflaRx (NASDAQ:IFRX) Sees Significant Increase in Short Interest

InflaRx (NASDAQ:IFRX) was the target of a large growth in short interest in the month of June. As of June 30th, there was short interest totalling 232,800 shares, a growth of 151.1% from the June 15th total of 92,700 shares. Based on an average daily volume of 177,000 shares, the short-interest ratio is currently 1.3 days.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Raymond James & Associates boosted its holdings in InflaRx by 7.9% in the fourth quarter. Raymond James & Associates now owns 175,279 shares of the company’s stock worth $286,000 after acquiring an additional 12,873 shares in the last quarter. Raymond James Financial Services Advisors Inc. raised its position in shares of InflaRx by 18.2% in the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 317,859 shares of the company’s stock valued at $518,000 after purchasing an additional 48,944 shares during the last quarter. Franklin Street Advisors Inc. NC boosted its stake in InflaRx by 49.9% in the 4th quarter. Franklin Street Advisors Inc. NC now owns 75,100 shares of the company’s stock worth $122,000 after purchasing an additional 25,000 shares in the last quarter. Finally, Ikarian Capital LLC boosted its stake in InflaRx by 2.4% in the 1st quarter. Ikarian Capital LLC now owns 704,987 shares of the company’s stock worth $1,086,000 after purchasing an additional 16,383 shares in the last quarter. Institutional investors own 42.39% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and set a $8.00 price objective on shares of InflaRx in a report on Monday, June 24th.

InflaRx Price Performance

Shares of NASDAQ IFRX opened at $1.63 on Friday. InflaRx has a 1-year low of $1.14 and a 1-year high of $4.35. The business has a fifty day moving average price of $1.52 and a 200 day moving average price of $1.56. The stock has a market capitalization of $95.97 million, a P/E ratio of -2.09 and a beta of 1.58.

InflaRx (NASDAQ:IFRX) last announced its earnings results on Wednesday, May 8th. The company reported ($0.19) EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.05. The firm had revenue of $0.04 million during the quarter, compared to the consensus estimate of $1.76 million. As a group, equities research analysts anticipate that InflaRx will post -0.81 earnings per share for the current fiscal year.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.